Why is the Creso Pharma (ASX:CPH) share price frozen today?

Creso is once again in a trading halt…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) enjoyed a very pleasing day of gains on Tuesday. The All Ords finished the day up 0.33% at 7,587.4 points. But one ASX share wasn't even trading today. That would be the Creso Pharma Ltd (ASX: CPH) share price.

Creso shares closed at a share price of 9.6 cents yesterday afternoon. And that's where they will be staying, at least for a while.

That's because Creso announced that it has requested a trading halt, effective this morning. The company has said that this precedes it "releasing an announcement", with the shares to remain halted until this announcement is made public, or until 2 December (Thursday this week).

And that's all we know for now.

A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

Creso shares notch third ASX trading halt for November

But this isn't Creso's first rodeo, as it were. This ASX cannabis share was also placed in a trading halt just last week on 23 November. Before that, there was another halt, that one on 16 November.

The latter was sparked by an ASX 'speeding ticket' after the company fell more than 9% that day. My Fool colleague Mitchell dived deeper into this at the time.

The former halt was initiated in order for the company to inform investors that the Australian Securities and Investments Commission (ASIC) had requested Creso to "produce certain documents to ASIC in connection with an ASIC investigation".

This notice also informed the market that "ASIC's investigation includes suspected contraventions by the Company [Creso], its officers, agents, employees and representatives in relation to trading in its securities". Creso stressed that "it should not be construed as an indication by ASIC that a contravention of the law has occurred, nor should it be considered a reflection upon any person or entity".

So today's announcement means that it is the third such trading halt Creso has experienced over just the month of November.

Given that the last two halts didn't contain much in the way of good news, shareholders will likely be nervously awaiting what the company has to say next.

Until then, it doesn't look like the Creso share price will be available for public trading.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »